References
- Brada M, Ajithkuma T V, Minniti G. Radiosurgery for pituitary adenomas. Clinical Endocrinology 2004; 61: 531–543
- Buvat J. Hyperprolactinemia and sexual function in men: a short review. International Journal of Impotence Research 2003; 15: 373–377
- Cheng W C, Yen M L, Hsu S H, Chen K H, Tsai K S. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Endocrine 2004; 23: 215–218
- Czeizel A, Kiss R, Racz K, Mohori K, Glaz E. Case-control cytogenetic study in offspring of mothers treated with Bromocriptine during early pregnancy. Mutation Research 1989; 210: 23–27
- Hall W A, Luciano M G, Doppman J L, Patronas N J, Oldfield E H. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Annals of International Medicine 1994; 120: 817–820
- Hoffman K L, Parsons G H, Allerdt L J, Brooks J M, Miles L EM. Elimination of ‘hook-effect’ in two-site immunoradiometric assays by kinetic rate analysis. Clinical Chemistry 1984; 30: 1499–1501
- Karunakaran S, Page R C, Wass J A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clinical Endocrinology (Oxf) 2001; 54: 295–300
- Lee S J, Yoo H J, Park S W, Choi M G. A case of cystic lymphocytic hypophysitis with cacosmia and hypopituitarism. Endocrinology Journal 2004; 51: 375–380
- Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. Journal of Clinical Endocrinology and Metabolism 2002; 87: 3180–3186
- Miller K K. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectrums 2004; 9: S28–S32
- Molitch M E. Pregnancy and the hyperprolactinaemic woman. New England Journal of Medicine 1985; 312: 1362
- Patel D D, Bhatavdekar J M, Chikhlikar P R, Ghosh N, Suthar T P, Shah N G, et al. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. Journal of Surgical Oncology 1996; 62: 86–92
- Peeva E, Venkatesh J, Michael D, Diamond B. Prolactin as a modulator of B cell function: implications for SLE. Biomedicine and Pharmacotherapy 2004; 58: 310–319
- Ricci E, Parazzini F, Motta T, Ferrari C I, Colao A, Clavenna A, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology 2002; 16: 791–793
- Saraiya H. Postburn galactorrhoea with refractory hypertrophic scars: role of obesity under scrutiny. Journal of Burn Care Rehabilitation 2003; 24: 392–394
- Schofl C, Schofl-Siegert B, Karstens J H, Bremer M, Lenarz T, Cuarezma J S, et al. Falsely low serum prolactin in two cases of invasive macroprolactinomas. Pituitary 2002; 5: 261–265
- Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia revisited: a study on 106 patients. Journal of Clinical Endocrinology and Metabolism 2002; 87: 581–588
- Wallaschofski H, Kobsar A, Sokolova O, Siegemund A, Stepan H, Faber R, et al. Differences in platelet activation by prolactin and leptin. Hormone and Metabolic Research 2004; 36: 453–457